Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "OPKO Health Reference Laboratories" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about OPKO Health Reference Laboratories for you to read. Along with our medical data and news we also list OPKO Health Reference Laboratories Clinical Trials, which are updated daily. BioPortfolio also has a large database of OPKO Health Reference Laboratories Companies for you to search.
Opko Health and Haemonetics are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk. Opko Health currently has a consensus price target of $12.10, suggesting a potential upside of 270.03%.
NEW YORK, Sept. 14, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of OPKO Health ("OPKO" or the "Company") (NASDAQ: OPK). Such investors are advised to contact ...
NEW YORK, NY / ACCESSWIRE / May 22, 2018 / Pomerantz LLP is investigating claims on behalf of investors of OPKO Health, Inc. ("OPKO" or the "Company") (NASDAQ: OPK). Such investors are advised to ...
OPKO Health has completed enrolment in a global pivotal Phase lll trial of somatrogon (hGH-CTP) for the treatment of growth...Read More... The post OPKO Health completes enrolment in Phase lll trial of somatrogon appeared first on Drug Development Technology.
OPKO Health (NASDAQ:OPK) reports financial results and business highlights for the three months ended March 31, 2018. As quoted in the press release: “We are pleased to report steady sequential-quarter growth for RAYALDEE and 4Kscore, as well as improvement in our lab business from Q4 of last year,” said Phillip Frost, Chairman and Chief Executive Officer of … Continued The post OPKO H...
Stock Monitor: Capricor Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on OPKO Health, Inc. (NASDAQ: ...
Science and technology company, Merck, has entered into an agreement with HistoCyte Laboratories, for the distribution of its portfolio of cell line reference products for immunohistochemistry and in situ hybridisation.
SAN FRANCISCO, Sept. 11, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in OPKO Health, Inc. (NASDAQ: OPK) to the firm's investigation into Read more...
The SEC announced the charges Friday, alleging the Opko CEO and nine others manipulated stock prices in "classic pump-and-dump schemes."
The company has used multi-dose disposable pen to deliver an investigational long-acting human growth hormone product, somatrogon. Somatrogon is a new molecular entity, which maintains the natural sequence The post Opko Health completes enrollment in phase 3 study of somatrogon in GHD children appeared first on Compelo Medical Devices.
OPKO Health, Inc. (NASDAQ: OPK) is pleased to confirm that The Nasdaq Stock Market has lifted the trading suspension of OPKO’s shares. As noted previously, OPKO and 19 other defendants, including Dr. Phillip Frost, its CEO and Chairman, were named in a Complaint filed on September 7 by the Securities and Exchange Commission (“SEC”). The Comp...
OPKO Health, Inc. (NASDAQ:OPK) has had trading in its common stock halted by The Nasdaq Stock Market, and the exchange has advised OPKO that the halt will continue until the company responds (to Nasdaq’s satisfaction) to the exchange’s request for information related to the previously reported lawsuit filed by the U.S. Securities and Exchange Commissio...
OPKO Health, Inc. (NASDAQ: OPK) provided the following comment on the lawsuit filed by the U.S. Securities and Exchange Commission earlier today. “OPKO learned today that the Securities and Exchange Commission has filed a lawsuit in the Southern District of New York against a number of individuals and entities, including OPKO and its CEO and Cha...
Public Company Edition: An SEC complaint alleges that the company, Opko CEO Frost and co-defendants bought penny stocks, pumped up...
Whether your experiment relies upon a reference-based genome assembly or mapping reads to a reference genome to identify variants, you need to choose a human reference genome assembly. But wait! You go to the FTP site of NCBI’s refseq and click on the Homo sapiens folder. There you are presented with two choices. Which one… The post Get to Know Your Reference Genome (GRCh37 vs GRCh38) appe...
The company, one of the largest on the Tel Aviv Stock Exchange, joins the exodus of dual-listed US biotech companies.
Merck, a leading science and technology company, has announced that it has entered into an agreement with HistoCyte Laboratories Ltd, Tyne, U.K., to be the exclusive multinational distributor of the company’s portfolio of cell line reference products for immunohistochemistry and in situ hybridization....
OPKO Health Inc. (OPK) has reported better-than-expected financial results for the first quarter ended March 31, 2018.
PierianDx, the leading clinical genomics technology company that enables precision medicine, announced today that TriCore Reference Laboratories will utilize the company’s Clinical Genomics WorkSpace™ (CGW) platform, the industry’s leading integrated workspace for genomic analytics, classification, interpretation and reporting. TriCore will join mor...
Cardinal Health and Bio-Rad Laboratories are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership. Cardinal Health has higher revenue and earnings than Bio-Rad Laboratories.